<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01972659</url>
  </required_header>
  <id_info>
    <org_study_id>KOU 2012 KAEK 144</org_study_id>
    <nct_id>NCT01972659</nct_id>
  </id_info>
  <brief_title>Effects of Magnesium Sulphate on Sugammadex Reversal of Rocuronium Induced Blockade in Gynaecology Patients</brief_title>
  <official_title>Effects of Magnesium Sulphate on Sugammadex Reversal of Rocuronium Induced Blockade in Gynaecology Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kocaeli University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kocaeli University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: The aim of this prospective study was to evaluate the effect of magnesium on the
      reversal of rocuronium-induced neuromuscular block by sugammadex.

      Methods: Eighty patients, aged 18 to 60 years, American Society of Anesthesiologists I-II,
      undergoing elective gynecological surgery were enrolled. Anaesthesia was induced with
      propofol and fentanyl and was maintained with 60% nitrous oxide and Oxygen in sevoflurane.
      The magnesium group received 50 milligram/kilogram (mg/kg) Magnesium intravenous (iv) as a
      bolus and 15 mg/kg/hour by continuous infusion until the completion of surgery. The placebo
      group received the equivalent volume of isotonic saline. For intubation, 0.6 mg/kg rocuronium
      was administered and 0.1 mg/kg was added when Train of four (TOF) counts reached 1 or more
      during the procedure. At the end of the surgery at a TOF count of 1, 4 mg/kg sugammadex iv
      was administered. Patients were observed until a TOF ratio of 0.9 was achieved.
      Patient-controlled analgesia with intravenous morphine was used postoperatively.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Inclusion criteria:

        -  American Society of Anesthesiologists physical status I or II

        -  18-60 years of age

        -  undergoing elective gynecological surgery

        -  requiring endotracheal intubation

      Exclusion criteria:

        -  Patients who had body mass index &gt; 35

        -  gastroesophageal reflux

        -  a history of allergy

        -  used medication known to interact with the drugs being used in this trial

        -  who experienced expected or unexpected difficulty during intubation or ventilation

        -  had neuromuscular disease

        -  hepatic or renal insufficiency

        -  pregnant

        -  were American Society of Anesthesiologists III or IV

        -  had a family history of malignant hyperthermia

        -  detection if low or high control plasma magnesium levels
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>TOF 0.9 Achieving Time</measure>
    <time_frame>end of the surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rocuronium Onset Time</measure>
    <time_frame>during the surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rocuronium Supplementation</measure>
    <time_frame>during surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative Morphine Consumption</measure>
    <time_frame>after 12 hour surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Pre-eclampsia Aggravated</condition>
  <arm_group>
    <arm_group_label>sugammadex and placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>sugammadex: 4 mg/kg iv bolus at the end of the surgery at a TOF count of 1 placebo: isotonic saline (%0.9 NaCl) 50 mg/kg iv bolus plus 15 mg/kg continuous infusion until the end of surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sugammadex and magnesium sulphate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>sugammadex: 4 mg/kg iv bolus at the end of the surgery at a TOF count of 1 magnesium: 50 mg/kg iv bolus plus continuous infusion until the end of surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Active comparator 50 mg/kg iv bolus plus 15 mg/kg continuous infusion</description>
    <arm_group_label>sugammadex and placebo</arm_group_label>
    <other_name>%0.9 NaCl</other_name>
    <other_name>isotonic saline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Magnesium Sulphate</intervention_name>
    <description>Experimental :
50 mg/kg bolus plus 15 mg/kg continuous infusion</description>
    <arm_group_label>sugammadex and magnesium sulphate</arm_group_label>
    <other_name>magnesium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sugammadex</intervention_name>
    <description>4 mg/kg iv bolus at the end of the surgery</description>
    <arm_group_label>sugammadex and placebo</arm_group_label>
    <arm_group_label>sugammadex and magnesium sulphate</arm_group_label>
    <other_name>bridion</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  female patients

          -  American Society of Anesthesiologists (ASA) physical status I or II

          -  18-60 years of age who were undergoing elective gynecological surgery

          -  requiring endotracheal intubation were enrolled in this prospective study.

        Exclusion Criteria:

          -  Patients who had body mass index &gt; 35

          -  gastroesophageal reflux

          -  a history of allergy

          -  used medication known to interact with the drugs being used in this trial

          -  who experienced expected or unexpected difficulty during intubation or ventilation

          -  had neuromuscular disease

          -  hepatic or renal insufficiency

          -  were pregnant

          -  had a family history of malignant hyperthermia

          -  detection if low or high control plasma magnesium levels
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zehra I. ARSLAN, Asst. Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Anesthesiology and Reanimation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kocaeli University Hospital</name>
      <address>
        <city>Kocaeli</city>
        <zip>41380</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 11, 2013</study_first_submitted>
  <study_first_submitted_qc>October 24, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 30, 2013</study_first_posted>
  <results_first_submitted>January 10, 2014</results_first_submitted>
  <results_first_submitted_qc>January 10, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 25, 2014</results_first_posted>
  <last_update_submitted>January 10, 2014</last_update_submitted>
  <last_update_submitted_qc>January 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 25, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kocaeli University</investigator_affiliation>
    <investigator_full_name>Zehra Ipek ARSLAN</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>sugammadex</keyword>
  <keyword>rocuronium</keyword>
  <keyword>magnesium</keyword>
  <keyword>female</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eclampsia</mesh_term>
    <mesh_term>Pre-Eclampsia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rocuronium</mesh_term>
    <mesh_term>Magnesium Sulfate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Sugammadex and Placebo</title>
          <description>sugammadex: 4 mg/kg iv bolus at the end of the surgery at a TOF count of 1 placebo: isotonic saline (%0.9 NaCl) 50 mg/kg iv bolus plus 15 mg/kg continuous infusion until the end of surgery
placebo: Active comparator 50 mg/kg iv bolus plus 15 mg/kg continuous infusion
sugammadex: 4 mg/kg iv bolus at the end of the surgery</description>
        </group>
        <group group_id="P2">
          <title>Sugammadex and Magnesium Sulphate</title>
          <description>sugammadex: 4 mg/kg iv bolus at the end of the surgery at a TOF count of 1 magnesium: 50 mg/kg iv bolus plus continuous infusion until the end of surgery
Magnesium Sulphate: Experimental :
50 mg/kg bolus plus 15 mg/kg continuous infusion
sugammadex: 4 mg/kg iv bolus at the end of the surgery</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>problems realted to acceleromyograph</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sugammadex and Placebo</title>
          <description>sugammadex: 4 mg/kg iv bolus at the end of the surgery at a TOF count of 1 placebo: isotonic saline (%0.9 NaCl) 50 mg/kg iv bolus plus 15 mg/kg continuous infusion until the end of surgery
placebo: Active comparator 50 mg/kg iv bolus plus 15 mg/kg continuous infusion
sugammadex: 4 mg/kg iv bolus at the end of the surgery</description>
        </group>
        <group group_id="B2">
          <title>Sugammadex and Magnesium Sulphate</title>
          <description>sugammadex: 4 mg/kg iv bolus at the end of the surgery at a TOF count of 1 magnesium: 50 mg/kg iv bolus plus continuous infusion until the end of surgery
Magnesium Sulphate: Experimental :
50 mg/kg bolus plus 15 mg/kg continuous infusion
sugammadex: 4 mg/kg iv bolus at the end of the surgery</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="36"/>
            <count group_id="B2" value="37"/>
            <count group_id="B3" value="73"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.3" spread="10.3"/>
                    <measurement group_id="B2" value="39.4" spread="10.6"/>
                    <measurement group_id="B3" value="40.1" spread="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>TOF 0.9 Achieving Time</title>
        <time_frame>end of the surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sugammadex and Placebo</title>
            <description>sugammadex: 4 mg/kg iv bolus at the end of the surgery at a TOF count of 1 placebo: isotonic saline (%0.9 NaCl) 50 mg/kg iv bolus plus 15 mg/kg continuous infusion until the end of surgery
placebo: Active comparator 50 mg/kg iv bolus plus 15 mg/kg continuous infusion
sugammadex: 4 mg/kg iv bolus at the end of the surgery</description>
          </group>
          <group group_id="O2">
            <title>Sugammadex and Magnesium Sulphate</title>
            <description>sugammadex: 4 mg/kg iv bolus at the end of the surgery at a TOF count of 1 magnesium: 50 mg/kg iv bolus plus continuous infusion until the end of surgery
Magnesium Sulphate: Experimental :
50 mg/kg bolus plus 15 mg/kg continuous infusion
sugammadex: 4 mg/kg iv bolus at the end of the surgery</description>
          </group>
        </group_list>
        <measure>
          <title>TOF 0.9 Achieving Time</title>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="0.6"/>
                    <measurement group_id="O2" value="2.1" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rocuronium Onset Time</title>
        <time_frame>during the surgery</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rocuronium Supplementation</title>
        <time_frame>during surgery</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Postoperative Morphine Consumption</title>
        <time_frame>after 12 hour surgery</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Sugammadex and Placebo</title>
          <description>sugammadex: 4 mg/kg iv bolus at the end of the surgery at a TOF count of 1 placebo: isotonic saline (%0.9 NaCl) 50 mg/kg iv bolus plus 15 mg/kg continuous infusion until the end of surgery
placebo: Active comparator 50 mg/kg iv bolus plus 15 mg/kg continuous infusion
sugammadex: 4 mg/kg iv bolus at the end of the surgery</description>
        </group>
        <group group_id="E2">
          <title>Sugammadex and Magnesium Sulphate</title>
          <description>sugammadex: 4 mg/kg iv bolus at the end of the surgery at a TOF count of 1 magnesium: 50 mg/kg iv bolus plus continuous infusion until the end of surgery
Magnesium Sulphate: Experimental :
50 mg/kg bolus plus 15 mg/kg continuous infusion
sugammadex: 4 mg/kg iv bolus at the end of the surgery</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Assistant Professor Dr Z Ipek ARSLAN AYDIN</name_or_title>
      <organization>Kocaeli University Medical Faculty</organization>
      <phone>00905325011339</phone>
      <email>zehraipek48@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

